ArticleThe Lancet. Oncology2024

Multi-organ immune-related adverse events from immune checkpoint inhibitors and their downstream implications: a retrospective multicohort study.

Guihong Wan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.